- Current timeline for drug development is 10-12 years and costs approximately $1-3 billion. Tevogen’s approach has the potential to shorten timelines and substantially reduce costs.
- Tevogen’s AI initiative, Tevogen.AI, will pursue two key objectives, applying machine learning to existing processes to accelerate drug development and lower costs, and using Microsoft’s industry leading AI tools to develop proprietary algorithms designed to decode the relationship between genetics and T cells.
WARREN, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shares details of its partnership with Microsoft (Nasdaq: MSFT) for Startups.
Through this partnership Tevogen.AI aims to achieve two key objectives. The first objective is to apply the principles of machine learning to rapidly expand Tevogen’s ExacTcell™ pre-clinical pipeline by performing key simulations based on the successful trial results of TVGN 489. This capability may allow Tevogen’s research team to analyze large datasets across the genome, yielding faster and more accurate target identification. The second objective uses Microsoft’s advanced AI tools to develop proprietary algorithms that decode the interactions between human leukocyte antigens (HLA) and T cells. This capability may expand Tevogen’s understanding of immune responses and identify new therapeutic opportunities, especially in areas with limited existing data.
Mittul Mehta, Chief Information Officer and Head of Tevogen.AI commented “Insights from the technical resources at Microsoft, the world’s leading AI company, identified which tools to utilize, thereby helping us build our data pipelines to aggregate and normalize the appropriate datasets across the viral spectrum. We aim to take these datasets and apply machine learning models to speed up target selection. Subsequently, the refined data will be used as part of our predictive AI technology to fulfil areas that have insufficient data thereby allowing us to address key interactions that haven’t been seen yet. Tevogen.AI will continue working with Microsoft to advance the predictive modeling by leveraging their expertise.”
“Through our partnership with Microsoft, we anticipate an initial reduction in timelines of about 10%, with further automation potentially allowing us to achieve reduction of up to 30%. This preclinical modeling not only accelerates our processes but also enhances accuracy, leading to direct and tangible cost savings. These advancements support our goal of bringing life-changing therapies to market in a faster and more cost-efficient manner,” said Dr. Neal Flomenberg, Tevogen Bio’s Chief Scientific Officer.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and numerous pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of experienced industry leaders and scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen related to the Business Combination; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
